Proprietary Organic Plant Based Pizza Dough Co

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client developed and operates a multi-market high-demand system capable of identifying criminal subjects in seconds. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. The system generates recurring revenue from major retailers. Our client's database is fed with crime and criminal data from over 28,000 sources that update and add new data to their system every day. A global technology agreement was recently signed by a major worldwide electronics manufacturer to integrate our client's system. This significant agreement with the major worldwide electronics manufacturer expands the system from single-enterprise sales to mass-market injection via this new customer's global customer base. The enterprise was designed to bridge the long-standing gap between surveillance video and subject identification and create a next-generation system for subject intelligence. The founder tells us: 'We spent significant time and resources to identify over 28,000 data source points and go through the process to obtain, extract, scrub, and continually update records. Our system and process continued to rapidly develop, allowing further increases in data digestion while completely automating the process. We remain the largest private database of criminals in the world. We developed a multi-market high-demand system capable of identifying criminal subjects in seconds. Whether identifying subjects from surveillance video, home security cameras, video doorbell cameras, or conducting compliance and risk mitigation, our solution and its 70 million+ database is a market-first product with no competition and is used by a variety of Fortune 500 blue-chip customers. The signing of a major worldwide electronics manufacturer to a global technology partnership will add our system to their security products, creating a mass-market injection and significant ARR stream.' With a sales, marketing, and business development team comprised of only 2 people, our client focused initially on penetrating the difficult and highly competitive market of loss prevention within Fortune 500 retailers. After the proprietary system demonstrated a successful track record in identifying subjects and deterring criminal activity, our client gained immediate visibility and has since gained nearly a dozen of the world's largest retailers as clients. Our client has disrupted antiquated identification processes within several of the largest markets, attracting the attention of global manufacturers such as the major worldwide electronics manufacturer's willing to integrate their technology. Our client developed a SaaS system, which provides its '4 I's' Intelligence, Information, Investigation, and Identification. The SaaS is a completed system and is fed with crime and criminal data from over 28,000 sources that update and add new data to the system every day. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. Our client's technology has been implemented by many of the largest companies in the world and is currently being integrated by one of the largest technology manufacturers in the world. The strategy is effective, and the reach of the technology is poised to be further expanded. Our client invented and made operational multiple processes and new technology. The system is not only completed and automated, but also proven in the marketplace. One of the achievements worthy of note is that our client's system was responsible for the largest Organized Retail Crime bust in US history. Our client's core competencies and strengths include the highly developed system with ownership of the largest private database of criminal subjects in the world, existing blue-chip customers, a global technology contract with a major worldwide electronics manufacturer, and a technology platform that is extremely valuable in multiple other markets that have not yet been approached. Our client's Intelligence obtains its database data from over 28,000 county, state, federal, and regulatory agency sources. Our client has automated the data digestion process to upload new records, and search/verify changed records several times per day. Once new and or changed data is recognized, an automated process will retrieve the data, categorize, and then implement into our client's system. Our client owns all processes, and websites which they will transfer in full to a buyer. Our client's 'ready to go,' profitable tech, and relationships will enable a buyer to be up and running immediately. NDA is required {LINK ABOVE} to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: See the CIM for details Financing: Offers and investment will be considered Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for Selling: To allow the business to rapidly expand world-wide

Our client sources an excellent quality bourbon that has a higher yield than a traditional 6-8-year aged bourbon. Due to the higher yield because of less evaporation, they are able to keep the MSRP very competitive and are growing rapidly. They partner with a smaller craft distillery as their co-packer in order to keep production costs down. The founder is a rising, Tennessee-based singer/songwriter with thousands of followers. He uses, and will continue to use, his social media and concerts to publicize the bourbon and allows fans to become partial minority owners of the brand, thus far garnering approximately $200,000 as of the beginning of December 2022. Since the launch of the bourbon brand in 2018 it has earned some of the largest and most prestigious awards which can be awarded in the spirit industry. 1) Named Top 6 in the World in Forbes 2) Featured in Billboard, Rolling Stone, Uproxx, American Songwriter 3) Platinum Los Angeles 4) Double Gold San Francisco (largest award in the world for whiskey to earn) 5) Double Gold New York International 6) Double Gold New York Best Fifty 7) Gold Las Vegas 8) Silver Denver Our client has created a supportive community of real fans who love both the founder's music and the bourbon. Our client has taken the brand as far as 26 states. They will soon expand into Canada and exporting to South Africa & Vietnam is on the horizon. The founder and his partner are willing to stay on the team to bring the Bourbon brand to a much higher national level with a well-capitalized strategic buyer or owner-operator who is passionate about the bourbon industry. An NDA is required to secure a comprehensive Confidential Information Memorandum (CIM). Growth & Expansion: In CIM - NDA Required. Financing: If the price and deal structure is right Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: Other Projects

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

The business manufactures and maintains process controllers servicing the water/wastewater, industrial, and institutional markets. Products are used in nuclear power plants, universities, hospitals, steel mills, paper mills etc. Two contract manufacturers make the products. One makes the products, assembles and drop ships them directly to customers. The other ships parts for final assembly at the Company's HQ. The business model has reduced overhead and the need for larger facilities. The Company has been through several incarnations since the late 1800's and into the1900s when early models of process controllers were invented. This legacy of innovation was nearly lost when the 2004 buyers, a private equity group, failed to implement adequate management and oversight of operations. When purchased and a new LLC established in 2019, the operation was distressed; innovation stalled and engineering on hold. The current owner, an industry-insider, knew what needed to be done, reduced manpower redundancy, but saved jobs and inspired innovation once again. The value-add potential seen in restructuring; reducing overhead, implementing operational efficiencies and improvements resulted in increased bottom-line profitability and the business' gross margin. Detailed Information Facilities: The 7,500 square foot industrial/office space rents for $4,700 per month. The lease extends through May 2024. About half of the space is open warehouse with offices around the perimeter. Competition: Three large multinational corporations are the most predominate competitors in the market that cannot compete with on price thanks to the greater flexibility in pricing. This flexibility also means the ability to offer more customization options to the customer. Other than lower price points, the Company offers great support & application-based solutions. Excellent support, outstanding products and digital marketing, have helped grow market share in since 2019. Growth & Expansion: The Company is on track for gaining market share in a variety of categories of controllers, and with the pending release of the new a next-generation controller more opportunities will open. Additionally, the Company was been awarded a contract for an international nuclear project. In the future, greater overhauls in various industries will be needed to accommodate greater automations. Many new opportunities that will originate with engineering department. The team will create drawings, and design controller configuration. Domestic and international oil and gas industry applications are still strong; natural gas pipelines require compression, measuring and refinery stations. There will be more opportunity in renewable energy, as the industry becomes more streamlined. To ensure long-range goals are reached, the Seller recommends the Buyer focus on making R&D investments, keep new product pipelines growing, and increase spending in the sales & marketing departments. Financing: TBD if structure and terms are acceptable. Support & Training: To ensure a smooth transition and ongoing success the Sellers will work with a buyer as needed for three months, and longer as a paid part-time consultant, as negotiated. Reason for Selling: Seller enjoys restructuring companies, once stabilized, it's onto the next rescue project!

With a previous background in insurance, the Seller opened this independent agency in 2014 and built it from the ground up. By emphasizing personalized service and trust, there are now 770 policies in force. Eighty-two percent are Medicare Advantage policies, while the other 18 percent are composed of prescription plans, Medicare supplement plans, and dental plans. Only 2 percent are healthcare plans for those under 65. Strategic investments in advertising through radio, TV, and social media have significantly boosted brand recognition, fueling an impressive 65% growth trajectory since 2021. Buyer Qualifications: Potential Buyers must have a direct appointment with Wellcare to be considered. NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

This profitable Company is a unique California medical network that can be customized to the needs of each individual client. The Company has years of experience in PPO. The business model generates recurring revenue and the technology allows the subscribing clients to customize the network to fit their own needs. The Company also offers several re-pricing options to payers. The Company reviews provider performance to assure compliance with the network's evidence-based treatment guidelines, improving outcomes and offers metrics germane to the medical treatment within the network, allowing payers to monitor performance. The Company is a resource for Group Medical Insurance Providers and Payers, and for Workers Comp Payers to create a custom network of highly qualified medical providers, specific to California. The Company's network and technology allow Payers and Employers to tailor their network to their own specific needs. The payers subscribe to the Company's network generating recurring revenue for the Company. NOTE: This is a re-listing of a major purchase opportunity for a rapidly expanding, profitable California medical network. The initial response to the original listing of this opportunity was huge. A large investment group signed a Letter of Intent To Purchase early on, thus removing the opportunity from the marketplace. The holder of the LOI, following numerous delays over many months, was unable to proceed due to unexpected internal problems separate from their signing the LOI or their completed due diligence. Therefore, this terrific opportunity is now again available for purchase. Our Client's business and profits continue to expand. They have re-listed this purchase opportunity at $3M (USD). This sale price, based on current revenues, growth and profits, should be recovered by a Buyer in short order. Please do not respond to this opportunity unless you will provide proof of funds prior to any demos or negotiations; i.e. the capability to make an acquisition of $3M dollar (USD). The Seller only wishes to work with interested Buyers who, once they are satisfied with their due diligence, are prepared to proceed immediately. We do ask for your understanding in these regards as our initial listing generated a very high volume of responses. NDA is required to secure first round of comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: Current rent is $1975 per month for the 1050 sq ft space. Many staff currently work from home, and some have remained in the office space in Tracy, California. Current lease extends through January 31, 2021, so the Buyer may choose to keep this office space or move the Business. The current space allows for social distancing and COVID compliance for those staff who continue to work in the office and not from home. Competition: This Company is unique in the industry and competes against large national players. The Company beats the competition by providing a higher level of customer service, customization of medical provider networks, and competes on price. Growth & Expansion: The Sellers have grown the business to its current level with a slim 'guerilla' marketing budget. An ideal Buyer would have a budget for marketing and advertising, as well as for staffing to handle more leads. With the right Buyer, this Company is primed to grow! Support & Training: As needed. Financing: Available with the right offer Reason for Selling: Retirement.